Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | PKLR | P30613 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5619307 | 0.71 | OPRM1 (0.40) | ALDH1A1CHRM1HSD11B1 | |
| SCHEMBL3442360 | 0.70 | ALDH1A1 (0.67) | MEN1KMT2AALDH1A1LMNACYP3A4 | |
| SCHEMBL2811768 | 0.69 | MEN1 (0.44) | MEN1KMT2AALDH1A1LMNACYP3A4 | |
| SCHEMBL23089800 | 0.69 | ALDH1A1 (0.58) | MEN1KMT2AALDH1A1LMNACYP3A4 | |
| SCHEMBL3441676 | 0.66 | ALDH1A1 (0.75) | MEN1KMT2AALDH1A1LMNACYP3A4 | |
| SCHEMBL5718112 | 0.66 | ALDH1A1 (0.67) | MEN1KMT2AALDH1A1KDM4ECYP3A4 | |
| SCHEMBL6103374 | 0.66 | ALDH1A1 (0.71) | ALDH1A1LMNAKDM4ETDP1 | |
| SCHEMBL3441634 | 0.66 | ALDH1A1 (0.52) | MEN1KMT2AALDH1A1LMNACYP3A4 | |
| SCHEMBL3742265 | 0.66 | KMT2A (0.36) | MEN1KMT2AALDH1A1LMNAPKM | |
| SCHEMBL25419787 | 0.65 | ALDH1A1 (0.48) | MEN1KMT2AALDH1A1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212973-A1 | CARBAMATE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2351749-A1 | CARBAMATE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2011-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212973-A1 | CARBAMATE COMPOUND OR SALT THEREOF | FAAH, FAAH2, TRPV1 | MEN1 3864/4885KMT2A 1097/4885ALDH1A1 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.